As Co-founder and Chief Scientific Officer of #VivetTherapeutics, Dr @Gloria Gonzalez-Aseguinolaza will be presenting 📢 at the upcoming #CTX Scientific & Family Meeting on the 28 June at 13.25 CST in Itasca, Illinois!
Join Gloria where she will provide valuable insights into ‘potential gene therapy for Cerebrotendinous Xanthomatosis (CTX) from CYP27AI KO mouse model’ to the families affected by leukodystrophy and the world’s most respected and knowledgeable leukodystrophy experts. CTX is a rare autosomal recessive genetic disorder that affects the body’s ability to metabolize fats known as cholesterols.
#Vivet is accelerating development of gene therapy product, VTX-806 as an effective treatment option to stop or reverse disease progression over the long-term, or potentially cure CTX in patients. Initial proof of concept data has shown solid efficacy with VTX-806 in a relevant animal model. Learn more about VTX-801 here https://bit.ly/3XqiChb.
The annual family conference presented by @CTX Alliance in collaboration with @United Leukodystrophy Foundation (#ULF) provides a well-rounded educational and networking experience aimed at empowering families effected by leukodystrophies around the world. The event provides a voice for members of the community and advocates for continued research and development of safe and efficient long-lasting therapies for leukodystrophies.